Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer. (31st December 2022)

• Record Type: Journal Article
• Authors: Zeng, Xiaohu; Zhu, Xin; Tian, Qikang; Tan, Xiaoke; Sun, Ning; Yan, Min; Zhao, Junwei; Wu, Xiangxiang; Li, Ruiqin; Zhang, Zhenqiang; Zeng, Huahui
• Is Part Of: Drug delivery. Volume 29:Number 1(2022)
• Page Start: 89
• Page End: 98
• Publication Date: 2022-12-31
• Subjects: Celastrol -- Chitosan oligosaccharide -- pancreatic cancer -- toxicity -- drug delivery system; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2021.2018521
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Celastrol is a promising antitumor drug candidate, but the poor water solubility and cytotoxicity limit its clinical application. Herein, we synthesized a Celastrol (Cel)-chitosan oligosaccharide (CSO) conjugate (Cel-CSO) for drug delivery. Celastrol was conjugated to a CSO backbone via amide bond formation, which was verified by infrared spectrum (IR) analyses. The Cel-CSO contained ∼10 wt% of Celastrol showed excellent aqueous solubility (18.6 mg/mL) in comparation with the parent Celastrol. Cel-CSO significantly inhibited tumor growth, induced apoptosis, and effectively suppressed tumor metastasis in human pancreatic cancer cells (BxPC-3). While the cytotoxicity of Cel-CSO in hepatic cells (HL7702) was lower than that of the free Celastrol. Cel-CSO enhanced the anticancer efficacy, promoted the circulation time of Celastrol, and reduced the subacute toxicity, which indicated that CSO can be a promising Celastrol delivery system for pancreatic cancer therapy.